Urvi Shukla

Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Anders Granholm, Marie Warrer Munch, Sheila Nainan Myatra et al. · Intensive Care Medicine · 2021 · 122 citations · Full text

Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia

Anders Granholm, Maj-Brit N. Kjær, Marie Warrer Munch et al. · Intensive Care Medicine · 2022 · 31 citations · Full text

Long Covid, Severe Hypoxaemia, Hematology +4

Higher vs lower doses of dexamethasone in patients with COVID‐19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan

Anders Granholm, B Vijayaraghavan, Maria Cronhjort et al. · Acta Anaesthesiologica Scandinavica · 2021 · 27 citations · Full text

Initial Experience of Critically Ill Patients with COVID-19 in Western India: A Case Series

Siddharth Chavali, Urvi Shukla, Prashant Mukta et al. · Indian Journal of Critical Care Medicine · 2020 · 25 citations · Full text

Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19

Zoe McQuilten, Balasubramanian Venkatesh, Vivekanand Jha et al. · NEJM Evidence · 2022 · 24 citations

Patient Selection, Anticoagulation Strategies, Covid-19 Epidemiology +20